MGMT methylation correlates with melphalan pelvic perfusion survival in stage III melanoma patients: a pilot study

Approximately 25% of melanoma patients with locoregional metastases are nonresponsive to new molecular target therapy and immunotherapy. When metastases are located in the pelvis, melphalan hypoxic perfusion can be an optional treatment. Because methylation of MGMT promoter increases the efficacy of...

Descripción completa

Detalles Bibliográficos
Autores principales: Guadagni, Stefano, Fiorentini, Giammaria, Clementi, Marco, Palumbo, Giancarlo, Masedu, Francesco, Deraco, Marcello, De Manzoni, Giovanni, Chiominto, Alessandro, Valenti, Marco, Pellegrini, Cristina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2017
Materias:
ORIGINAL ARTICLES: Translational research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5592983/
https://www.ncbi.nlm.nih.gov/pubmed/28486243
http://dx.doi.org/10.1097/CMR.0000000000000367

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5592983/
https://www.ncbi.nlm.nih.gov/pubmed/28486243
http://dx.doi.org/10.1097/CMR.0000000000000367

Ejemplares similares